Fig. 3From: Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world studyForest plot of the 3-year DFS rate in key subgroups of adjuvant chemotherapy after PSM. RD, rate difference in 3-year DFS between the two groupsBack to article page